相关实验视频

Updated: Jul 13, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

在患有复发性上皮卵巢癌的患者中,PARPis继PARPis:一个单一的机构经验

Hua Yuan¹, Tonghui Wang², Hongwen Yao¹

¹Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Journal of ovarian research

|September 27, 2025

概括

用聚ADP - 核糖) 聚合酶抑制剂 (PARPis) 进行复试,在复发的上皮卵巢癌 (EOC) 中显示出临床益处,特别是在BRCA突变或对先前化疗完全反应的患者中. 一些患者经历了PARPi重新治疗的长期好处.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

复发的上皮卵巢癌 (EOC) 在治疗疗效方面存在挑战.
聚ADP-ribose) 聚合酶抑制剂 (PARPis) 是EOC的关键疗法,但可以产生耐药性.
了解PARPi重新挑战的有效性对于优化患者的治疗结果至关重要.

研究的目的:

为了评估PARPi维护治疗的临床疗效,在中国患者中重新挑战复发性EOC.
评估PARPi重新挑战后的治疗模式和下一次治疗的时间 (TTNT).
为了确定可以从PARPi再治疗中获益最多的患者子组.

主要方法:

对31名初级EOC患者的回顾性分析,这些患者接受了两种PARPi维持治疗.
纳入标准:完全响应 (CR) 或部分响应 (PR) 以往的化疗.
评估临床和病理变量,治疗方式,结果和TTNT.

主要成果:

在64.5%的患者中,存在BRCA1/2突变. 一线 (PARPi1) 和二线 (PARPi2) PARPi治疗的中位持续时间分别为11.2个月和4.8个月.
中位数TTNT1为12.4个月,TTNT2为7.7个月. BRCA1/2突变与明显更好的TTNT1 (17.3 vs 10.4个月) 相关.
以往化疗的CR与明显更好的TTNT1 (16.4vs7.6个月) 和TTNT2 (11.1vs4.9个月) 相关联. 观察到贫血和血小板减少,在大多数受影响的患者中,在PARPi2治疗期间复发.

结论:

PARPi重新挑战可能有利于患有PARPi耐药性复发性EOC的患者,特别是那些在先前化疗后获得CR的患者.
患有BRCA1/2突变的患者更有可能从PARPi重新治疗中受益.
贫血和血小板减少是PARPi重试期间常见的不良事件,尽管严重事件并不频繁. 一些患者从重新治疗中获得的益处比初始治疗更长.

关键词:

在PARPis之后的PARPis.复发的上皮卵巢癌卵巢癌的复发

更多相关视频

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

相关概念视频

Long-patch Base Excision Repair

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:

Restarting Stalled Replication Forks

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart, a...